Peripheral Artery Disease, the Factor Xa Inhibitor Rivaroxaban, and the Role of the Podiatrist
JaypeeDigital | eBook Reader
Reversal of Apixaban and Rivaroxaban Anticoagulation by Andexanet Alfa in ANNEXA-A and ANNEXA-R as Assessed by Non-Tissue Factor-Initiated Thrombin Generation Independent of Tissue Factor Pathway Inhibitor - European Medical Journal
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring | Thrombosis Journal | Full Text
Update on laboratory testing and hemostasis assessment in patients receiving direct oral anticoagulants (DOACs) - ScienceDirect
The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants. | Semantic Scholar
Rivaroxaban for Stroke Prevention in Atrial Fibrillation
New oral anticoagulant drugs – mechanisms of action | Earl's View
Perioperative Management of New Anticoagulants: Novel Drugs and Concepts - Anesthesia Patient Safety Foundation
Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease | American Society of Nephrology
Mechanism of action of dabigatran, rivaroxaban and warfarin. | Download Scientific Diagram
Twitter 上的Arie Blitz, MD, MBA:"#Apixaban to Prevent #VTE in Patients With Cancer https://t.co/uC5076Lx6C via @practiceupdate #oncology https://t.co/v3AkMYi6FA" / Twitter